[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359021-105":59,"doc-detail-359021-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","cancer-therapy-related-cardiac-dysfunction-in-breast-cancer-patients-receiving-combination-therapy-of-candesartan-and-carvedilol","Cancer Therapy-Related Cardiac Dysfunction in Breast Cancer Patients Receiving Combination Therapy of Candesartan and Carvedilol","","Primary prevention of cancer therapy-related cardiac dysfunction (CTRCD) with renin-angiotensin system inhibitors and beta-blockers remains controversial. This prospective longitudinal study assessed incidence, severity, and predictors of CTRCD in 851 breast cancer patients with normal LVEF scheduled for chemotherapy and/or trastuzumab. Patients received candesartan plus carvedilol and underwent serial 3D echocardiography before therapy, every 3 months during, 6 months after, and annually thereafter. CTRCD developed in 24.6% with predominantly mild severity, and predictors included older age, hypertension, baseline LVEF/GLS, and stage II+ disease.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cancer-therapy-related-cardiac-dysfunction-in-breast-cancer-patients-receiving-combination-therapy-of-candesartan-and-carvedilol/359021/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cancer-therapy-related-cardiac-dysfunction-in-breast-cancer-patients-receiving-combination-therapy-of-candesartan-and-carvedilol/359021.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main purpose?","Question",{"text":112,"@type":113},"To investigate the incidence, severity, and predictors of cancer therapy-related cardiac dysfunction (CTRCD) under primary prevention therapy with candesartan plus carvedilol.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Who were the participants and how was therapy administered?",{"text":117,"@type":113},"The study included 851 breast cancer patients with normal LVEF scheduled for chemotherapy and/or trastuzumab. Candesartan plus carvedilol began on the first day of chemotherapy or trastuzumab and continued during and after cancer therapy.",{"name":119,"@type":110,"acceptedAnswer":120},"How was CTRCD defined and measured over time?",{"text":121,"@type":113},"CTRCD was defined using European Society of Cardiology criteria based on LVEF and global longitudinal strain (GLS) from serial real-time 3D echocardiography.",{"name":123,"@type":110,"acceptedAnswer":124},"Which factors were associated with developing CTRCD?",{"text":125,"@type":113},"Older age, hypertension, baseline LVEF and GLS, and stage II or higher disease were associated with CTRCD risk; in patients receiving anthracyclines and/or trastuzumab, hypertension predicted CTRCD in both low and intermediate-to-high baseline cardiovascular toxicity risk groups.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},359021,1790387718,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":36,"preview_page_count":19,"preview_urls":149},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","J Korean Med Sci. 2026 Mar 16;41(10):e92 [https://doi.org/10.3346/jkms.2026.41.e92](https://doi.org/10.3346/jkms.2026.41.e92)[ ](https://doi.org/10.3346/jkms.2026.41.e92)eISSN 1598-6357·pISSN 1011-8934  \nOriginal Article  \nCardiovascular Disorders  \nReceived: Feb 12, 2025  \nAccepted: Jun 30, 2025  \nPublished online: Feb 19, 2026  \nAddress for Correspondence:  \nChan Seok Park, MD, PhD  \nDivision of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 327 Sosa-ro, Wonmi-gu, Bucheon 14647, Republic of Korea.  \nEmail: [chanseok2002@gmail.com](chanseok2002@gmail.com)  \n© 2026 The Korean Academy of Medical Sciences.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nORCID iDs  \nJeong-Eun Yi  [https://orcid.org/0000-0003-2614-6983](https://orcid.org/0000-0003-2614-6983)[ ](https://orcid.org/0000-0003-2614-6983)[Woo-Baek Chung](Woo-Baek Chung)  [https://orcid.org/0000-0002-6933-2957](https://orcid.org/0000-0002-6933-2957)[ ](https://orcid.org/0000-0002-6933-2957)Jiyoung Rhu  [https://orcid.org/0000-0002-9173-5445](https://orcid.org/0000-0002-9173-5445)[ ](https://orcid.org/0000-0002-9173-5445)Chan Seok Park  [https://orcid.org/0000-0002-3481-6206](https://orcid.org/0000-0002-3481-6206)  \nFunding  \nThe Catholic Medical Center Research Foundation made in the program of 2021.  \nDisclosure  \nThe authors have no potential conflicts of interest to disclose.  \nCancer Therapy-Related Cardiac Dysfunction in Breast Cancer Patients Receiving Combination Therapy ofCandesartan and Carvedilol for Primary Prevention: A Prospective Longitudinal Study  \nJeong-Eun Yi ,1,2 Woo-Baek Chung ,1,3 Jiyoung Rhu ,4 and Chan Seok Park  1,5  \n1Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, Korea  \n2Division of Cardiology, Department of Internal Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea  \n3Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea  \n4Department of Surgery, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea  \n5Division of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea  \nABSTRACT  \nBackground: The use of renin-angiotensin system inhibitors and beta-blockers for primary prevention of cancer therapy-related cardiac dysfunction (CTRCD) remains controversial. This study investigated the incidence, severity and predictors of CTRCD undercardioprotective therapy with a combination of candesartan and carvedilol.  \nMethods: We included 851 subjects with a normal left ventricular ejection fraction (LVEF)(> 55%) who were scheduled to receive chemotherapy and/or trastuzumab (TZ) for breast cancer. Candesartan plus carvedilol were administered on the first day of chemotherapy or TZ and continued during and after cancer therapy. Patients underwent serial real-time threedimensional (3D) echocardiograms before initiation of chemotherapy or TZ, every 3 months during cancer therapy, 6 months after completion of cancer therapy, and annually thereafter. CTRCD was defined by the European Society of Cardiology definitions using LVEF and global longitudinal strain (GLS) derived from 3D-echocardiographic images.  \nResults: A total of 577 patients (257 anthracycline [AC]/non-TZ, 111 AC/TZ, 47 non-AC/TZ, and 162 non-AC/non-TZ) were analyzed. During a median follow-up of 17.9 months, 24.6% of patients (","cbCait8ImHpnPypf","https://ap.wps.com/l/cbCait8ImHpnPypf","pdf",1097509,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Author Contributions","[{\"question\":\"What was the study’s main purpose?\",\"answer\":\"To investigate the incidence, severity, and predictors of cancer therapy-related cardiac dysfunction (CTRCD) under primary prevention therapy with candesartan plus carvedilol.\"},{\"question\":\"Who were the participants and how was therapy administered?\",\"answer\":\"The study included 851 breast cancer patients with normal LVEF scheduled for chemotherapy and/or trastuzumab. Candesartan plus carvedilol began on the first day of chemotherapy or trastuzumab and continued during and after cancer therapy.\"},{\"question\":\"How was CTRCD defined and measured over time?\",\"answer\":\"CTRCD was defined using European Society of Cardiology criteria based on LVEF and global longitudinal strain (GLS) from serial real-time 3D echocardiography.\"},{\"question\":\"Which factors were associated with developing CTRCD?\",\"answer\":\"Older age, hypertension, baseline LVEF and GLS, and stage II or higher disease were associated with CTRCD risk; in patients receiving anthracyclines and/or trastuzumab, hypertension predicted CTRCD in both low and intermediate-to-high baseline cardiovascular toxicity risk groups.\"}]","Cancer Therapy-Related Cardiac Dysfunction in Breast Cancer Patients Receiving Combination Therapy of Candesartan and Carvedilol | PDF",1790135887,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/21043a3072600b0d864beeb66cced01a.webp",983,1310,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3d1f54ca338c5737ea8bc18fd2d94cc.webp",982,1309,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec7dcae1d22ce35070d74cc369256f49.webp",981,1308,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e02f56aed3670e3d6e134165f5e9419a.webp",980,1306]